price feb usd
what new result guidanc outlin path forward support
initi revenu earn outlook came
consensu expect focu instead manag comment around
expect stabil hcv franchis key driver uncertainti mid-
year revenue/earn stabil hcv eventu growth driven
strength hiv portfolio like next expect
investor look past continu near-term pressur instead focu
long-term outlook prospect growth asset inde
highlight hiv busi expect launch b/f/taf
oncolog franchis includ like portfolio expans strateg
key driver transit back growth yescarta launch
remain slow believ larg expect initi focu remain
execut center expans addit view pipelin larg
underappreci highlight key readout next
potenti drive upsid overal continu see valuat disconnect
share near-term headwind remain core focu reiter buy
rate slightli decreas pt follow today result
takeaway analysi
result show modest beat product dynam larg expect
top-lin result quarter street
estim nearli across board total revenu vs
dbe vs consensu expect hcv franchis
decreas quarter quarter price pressur competit
dynam continu grow vs dbe vs consensu
hiv busi provid anoth strong quarter quarter
sequenti growth vs dbe vs consensu overal earn
larg in-lin non-gaap ep vs dbe vs
guidanc bit light hcv manag commentari show
reason encourag manag guid consensu
forecast hcv revenu vs dbe vs
believ investor expect also trend neg well
suggest downsid estim may factor signicantli
go forward importantli howev compani suggest potenti
stabil mid-year potenti signal end sizabl
revenu declin impact growth outlook
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
share past sever year hcv market develop
duopoli believ market dynam like acceler steady-
state much faster new assumpt still take
major share split go forward
long-term product dynam appear suggest return growth
hcv franchis domin theme share
past sever year up- down-sid hcv
revenu begin stabil focu begin shift back
area outlook robust inde hcv busi
begin stabil term revenu market share trend
expect investor focu shift growth potenti pipeline/rec
launch asset includ b/f/taf regimen hiv inde
product continu oset hcv eros expect
emerg slowli modest growth stori
hcv still matter stabil good thing part longer-
term bullish outlook disconnect share
see underappreci valu hcv revenu tail
manag guid stabil middl year investor
better understand long-term dynam should/could look
like worth notabl patent protect
despit bearish view franchis re-fram
pipelin also emerg key read-out next
investor focu larg remain core hiv hcv franchis
potenti emerg pipelin next
key long-term upsid inde manag continu highlight
emerg leadership nash key updat sever
program expect notabl data fxr agonist
expect later year like easl well continu progress
late-stag selonsertib program pivot data like importantli
compani plan begin combin studi later year
given potenti activ mechan hold promis
view beyond nash rst data lgotinib program
expect although robust dataset expect
ultim nash inamm lgotinib
believ pipelin hold potenti sever blockbust asset
larg overlook current level data begin read-out
expect upsid potenti
capit alloc still top-of-mind manag reiter
desir expand portfolio extern opportun
importantli believ long-term goal gilead becom
leader oncolog cell therapi believ compani
could expand therapeut modal would also
complementari and/or addit exist cell therapi platform
inde believ target i/o approach could prove
beneci ad car-t could also benet gilead
provid stand-alon product well addit manag also
note desir nd asset improv upon enhanc exist
technolog ie potenti lessen side eect improv antigen
target henc believ increment addit
gene-edit technolog possibl well overal believ
compani like repeat lesson last year build upon grow
capabl oncolog drug develop deploy capit
strive toward goal leader space
yescarta still build phase need time market develop
think investor far give pass modest earli revenu
launch progress believ bar move higher mani
access reimburs issu presum go away importantli
believ gilead success optim patient cancer care
center experi import commerci success inde
product label car-t like ultim appear
similar dierent experi reliabl could prove
import dierenti compani highlight rst mover
advantag area could abl garner loyalty/shar
base earli experi obvious focu
yescarta revenu growth execut get center run
also critic continu progress reimburs side
hiv trend remain strong drive growth go forward
focu shift away hcv expect much near-term
convers hiv franchis encourag
recent trend space increment catalyst inde
given compani success histori hiv market expect
b/f/taf launch well-execut absorb quickli
medic commun ie rapid guidelin updat addit launch
see upsid franchis solid continu uptak
genvoya descovi although potenti sourc b/f/taf patient
could come dolutegravir descovi switch patient given clear
market prefer taf-bas regimen
chang model
updat model reect result addit
adjust estim account guidanc includ manag
commentari around expect hcv revenu specic decreas
hcv revenu estim increas
hiv revenu estim account
continu growth taf-bas regimen includ expect b/f/taf
launch expect later year overal decreas revenu
estim well adjust expens estim
follow compani guidanc shown figur decreas non-
ep model chang slightli decreas pt
forecast ratio
actual vs db estim chang model
figur result vs estim chang model
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //gm db com/ger/disclosure/
disclosuredirectori eqsr asid within report import conict disclosur also found http //gm db com/equ disclosur lookup legal
tab investor strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
deutsch bank and/or aliat make market equiti secur issu compani
deutsch bank and/or aliat own one percent class common equiti secur
compani calcul comput method requir us law
deutsch bank and/or aliat expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or aliat receiv non-invest bank relat compens
compani within past year
import disclosur requir non-u regul
